Answer
No, eltrombopag’s safety and efficacy have not been established in children and adolescents under 18 with chronic hepatitis C-related thrombocytopenia or severe aplastic anaemia.
Sources for this answer
- Revolade film-coated tabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.2 Posology and method of administration · Version 28Document updated
Sources checked